Literature DB >> 9493583

The canine factor VIII cDNA and 5' flanking sequence.

C Cameron1, C Notley, S Hoyle, L McGlynn, C Hough, S Kamisue, A Giles, D Lillicrap.   

Abstract

Factor VIII is a trace plasma glycoprotein involved as a cofactor in the activation of factor X by factor IXa. Inherited deficiency of factor VIII results in the X-linked bleeding disorder hemophilia A which has been documented in humans, horses, sheep and dogs. In this report, the putative proximal promoter, 5' untranslated region, complete coding sequence and 3' untranslated region of the canine factor VIII gene have been characterized. When compared to the human gene, the 5' flanking region shows conservation of transcription factor binding sites in the 5' untranslated region. Alignment of the amino acid sequence with that of the previously reported human, mouse and pig proteins demonstrates sequence identity of between 77 and 92% for the A1, A2, A3, C1 and C2 domains but an identity of only between 44 and 62% for the central B domain. The three thrombin cleavage sites are conserved in the canine sequence as are the protein C cleavage sites and the von Willebrand factor binding region. In addition, all six tyrosine residues that are known to undergo sulfation in the human protein are conserved in the dog. The 3' untranslated region of the canine gene extends 1.5 kilobases. The initial 700 basepairs of this sequence are highly GC rich and the sequence terminates with 2 alternative potential polyadenylation sites. The knowledge of this sequence, in combination with a well described canine model of hemophilia A, provides the necessary starting point for studies addressing the long-term evaluation of factor VIII gene therapy using a homologous transgene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9493583

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

Review 1.  Gene therapy for the hemophilias.

Authors:  M A Kay; K High
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 2.  Adeno-associated virus-mediated gene transfer for hemophilia B.

Authors:  Katherine A High
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 3.  Endothelial progenitor cell-based therapy for hemophilia A.

Authors:  Hideto Matsui
Journal:  Int J Hematol       Date:  2012-02       Impact factor: 2.490

Review 4.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

Review 5.  Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.

Authors:  Jun-ichi Ori; Ichiro Tanaka; Yoko Kubota; Midori Shima; Tomoko Matsumoto; Koichi Yoshida; Yoshihiko Sakurai; Akira Yoshioka
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

6.  The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Authors:  Jay N Lozier; Amalia Dutra; Evgenia Pak; Nan Zhou; Zhili Zheng; Timothy C Nichols; Dwight A Bellinger; Marjorie Read; Richard A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

Review 7.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

8.  Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.

Authors:  Denise E Sabatino; Christian Furlan Freguia; Raffaella Toso; Andrey Santos; Elizabeth P Merricks; Haig H Kazazian; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

9.  Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.

Authors:  J M Staber; M J Pollpeter; C-G Anderson; M Burrascano; A L Cooney; P L Sinn; D T Rutkowski; W C Raschke; P B McCray
Journal:  Gene Ther       Date:  2017-09-14       Impact factor: 5.250

10.  The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis.

Authors:  Katherine A High
Journal:  Trans Am Clin Climatol Assoc       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.